222 related articles for article (PubMed ID: 31176047)
1. High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm.
Bendifallah S; Ilenko A; Daraï E
J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):863-871. PubMed ID: 31176047
[TBL] [Abstract][Full Text] [Related]
2. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
Gultekin M; Guler OC; Yuce Sari S; Akkus Yildirim B; Onal C; Celik H; Yuce K; Ayhan A; Arik Z; Kose F; Altundag O; Zoto Mustafayev T; Atalar B; Bolukbasi Y; Yildiz F
J Obstet Gynaecol; 2021 Apr; 41(3):414-420. PubMed ID: 32347768
[TBL] [Abstract][Full Text] [Related]
3. Pattern of recurrence in patients with endometrial cancer: A retrospective study.
Vizza E; Cutillo G; Bruno V; Sperduti I; Mancini E; Baiocco E; Chiofalo B; Cicchillitti L; Certelli C; Zampa A; Piccione E; Corrado G
Eur J Surg Oncol; 2020 Sep; 46(9):1697-1702. PubMed ID: 32204935
[TBL] [Abstract][Full Text] [Related]
4. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
[TBL] [Abstract][Full Text] [Related]
5. [European guidelines (ESMO-ESGO-ESTRO consensus conference) for the management of endometrial cancer].
Ballester M; Bendifallah S; Daraï E
Bull Cancer; 2017 Dec; 104(12):1032-1038. PubMed ID: 29173977
[TBL] [Abstract][Full Text] [Related]
6. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
[TBL] [Abstract][Full Text] [Related]
7. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
8. The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study.
Buda A; Restaino S; Di Martino G; De Ponti E; Monterossi G; Dinoi G; Magni S; Quagliozzi L; Dell'Orto F; Ciccarone F; Lamanna M; Scambia G; Landoni F; Fanfani F
Eur J Surg Oncol; 2018 Oct; 44(10):1562-1567. PubMed ID: 30077521
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in endometrial cancer.
Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; Casado Saenz E
Cancer Chemother Pharmacol; 2020 Mar; 85(3):477-486. PubMed ID: 31950214
[TBL] [Abstract][Full Text] [Related]
10. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
Bendifallah S; Ouldamer L; Lavoue V; Canlorbe G; Raimond E; Coutant C; Graesslin O; Touboul C; Collinet P; Daraï E; Ballester M;
Gynecol Oncol; 2017 Jan; 144(1):107-112. PubMed ID: 27789083
[TBL] [Abstract][Full Text] [Related]
11. Stage IB endometrial cancer. Does lymphadenectomy replace adjuvant radiotherapy?
Bottke D; Wiegel T; Kreienberg R; Kurzeder C; Sauer G
Strahlenther Onkol; 2007 Nov; 183(11):600-4. PubMed ID: 17960334
[TBL] [Abstract][Full Text] [Related]
12. Is there any benefit of paraaortic field irradiation in pelvic lymph node positive endometrial cancer patients? A propensity match analysis.
Onal C; Yuce Sari S; Akkus Yildirim B; Gultekin M; Guler OC; Yildiz F
J Obstet Gynaecol; 2020 Oct; 40(7):1012-1019. PubMed ID: 31793400
[TBL] [Abstract][Full Text] [Related]
13. Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.
Kim TH; Kim HS; Kim TJ; Chang SJ; Kim DY; Ryu SY; Kim BG; Kim YT; Bae DS; Ryu HS; Nam JH
Gynecol Oncol; 2016 Jun; 141(3):440-446. PubMed ID: 27020700
[TBL] [Abstract][Full Text] [Related]
14. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
15. Analysis of outcome of Stage I-III endometrial cancer treated with systematic operation omitting paraaortic lymphadenectomy.
Kyo S; Hashimoto M; Maida Y; Mizumoto Y; Nakamura M; Takakura M; Inoue M
Eur J Gynaecol Oncol; 2007; 28(3):170-3. PubMed ID: 17624080
[TBL] [Abstract][Full Text] [Related]
16. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.
Liang LW; Perez AR; Cangemi NA; Zhou Q; Iasonos A; Abu-Rustum N; Alektiar KM; Makker V
Int J Gynecol Cancer; 2016 Mar; 26(3):497-504. PubMed ID: 26825840
[TBL] [Abstract][Full Text] [Related]
17. Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer.
Fleming ND; Soliman PT; Westin SN; dos Reis R; Munsell M; Klopp AH; Frumovitz M; Nick AM; Schmeler K; Ramirez PT
Int J Gynecol Cancer; 2015 Oct; 25(8):1437-44. PubMed ID: 26332387
[TBL] [Abstract][Full Text] [Related]
18. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
[TBL] [Abstract][Full Text] [Related]
19. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
